As for MC38 mouse model, both GSDME and αPD1 inhibited the tumor growth with CD8+T cells increased and the combined group had the highest number of activated CD8+T cells to secret IL2, TNFα, GZMB, and PFN, leading to the smallest volume and weight of tumors, which consolidated the positive efficacy of GSDME-induced CD8+T immunotherapy under treatment of αPD1in MSI CRC animal model. The gene discussed is CD8A; the disease is neoplasm.